Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography.

Seneca N, Finnema SJ, Laszlovszky I, Kiss B, Horváth A, Pásztor G, Kapás M, Gyertyán I, Farkas S, Innis RB, Halldin C, Gulyás B.

Psychopharmacology (Berl). 2011 Dec;218(3):579-87. doi: 10.1007/s00213-011-2343-z.

2.

Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.

Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyán I, Agai-Csongor E, Domány G, Tihanyi K, Adham N, Szombathelyi Z.

J Pharmacol Exp Ther. 2010 Apr;333(1):328-40. doi: 10.1124/jpet.109.160432.

3.

Brain uptake and distribution of the dopamine D3 /D2 receptor partial agonist [11 C]cariprazine: an in vivo positron emission tomography study in nonhuman primates.

Tóth M, Varrone A, Steiger C, Laszlovszky I, Horváth A, Kiss B, Gyertyán I, Adham N, Halldin C, Gulyás B.

Synapse. 2013 May;67(5):258-64. doi: 10.1002/syn.21631.

PMID:
23238770
4.

Evaluation of dopamine D₂/D₃ and serotonin 5-HT₂A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography.

Nakazawa S, Yokoyama C, Nishimura N, Horisawa T, Kawasaki A, Mizuma H, Doi H, Onoe H.

Psychopharmacology (Berl). 2013 Jan;225(2):329-39. doi: 10.1007/s00213-012-2815-9.

PMID:
22868411
5.

Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.

Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S.

Am J Psychiatry. 2007 Sep;164(9):1411-7.

PMID:
17728427
6.

Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.

Tateno A, Arakawa R, Okumura M, Fukuta H, Honjo K, Ishihara K, Nakamura H, Kumita S, Okubo Y.

J Clin Psychopharmacol. 2013 Apr;33(2):162-9. doi: 10.1097/JCP.0b013e3182825bce.

PMID:
23422369
7.

Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).

Vernaleken I, Fellows C, Janouschek H, Bröcheler A, Veselinovic T, Landvogt C, Boy C, Buchholz HG, Spreckelmeyer K, Bartenstein P, Cumming P, Hiemke C, Rösch F, Schäfer W, Wong DF, Gründer G.

J Clin Psychopharmacol. 2008 Dec;28(6):608-17. doi: 10.1097/JCP.0b013e31818ba2f6.

PMID:
19011428
8.
9.

Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents.

Gyertyán I, Kiss B, Sághy K, Laszy J, Szabó G, Szabados T, Gémesi LI, Pásztor G, Zájer-Balázs M, Kapás M, Csongor EÁ, Domány G, Tihanyi K, Szombathelyi Z.

Neurochem Int. 2011 Nov;59(6):925-35. doi: 10.1016/j.neuint.2011.07.002.

PMID:
21767587
10.

Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study.

Chou YH, Halldin C, Farde L.

Psychopharmacology (Berl). 2003 Mar;166(3):234-40.

PMID:
12589516
11.

A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.

Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G.

Am J Psychiatry. 2004 May;161(5):818-25.

PMID:
15121646
12.

Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457.

Takahata K, Ito H, Takano H, Arakawa R, Fujiwara H, Kimura Y, Kodaka F, Sasaki T, Nogami T, Suzuki M, Nagashima T, Shimada H, Kato M, Mimura M, Suhara T.

Psychopharmacology (Berl). 2012 Jul;222(1):165-72. doi: 10.1007/s00213-011-2633-5.

PMID:
22237854
13.

Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.

Suzuki T, Graff-Guerrero A, Uchida H, Remington G, Caravaggio F, Borlido C, Pollock B, Mulsant B, Deluca V, Ismail Z, Mamo D.

Psychopharmacology (Berl). 2013 Jul;228(1):43-51. doi: 10.1007/s00213-013-3012-1.

14.
15.

Use of PET and the radioligand [carbonyl-(11)C]WAY-100635 in psychotropic drug development.

Andrée B, Halldin C, Thorberg SO, Sandell J, Farde L.

Nucl Med Biol. 2000 Jul;27(5):515-21.

PMID:
10962260
16.

Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, [11C]RGH-1756 in the monkey brain.

Sóvágó J, Farde L, Halldin C, Langer O, Laszlovszky I, Kiss B, Gulyás B.

Neurochem Int. 2004 Oct;45(5):609-17.

PMID:
15234102
17.

Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA.

Finnema SJ, Halldin C, Bang-Andersen B, Gulyás B, Bundgaard C, Wikström HV, Farde L.

Synapse. 2009 May;63(5):378-89. doi: 10.1002/syn.20615.

PMID:
19173265
18.

Occupancy of dopamine D2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA.

Seneca N, Zoghbi SS, Skinbjerg M, Liow JS, Hong J, Sibley DR, Pike VW, Halldin C, Innis RB.

Synapse. 2008 Oct;62(10):756-63. doi: 10.1002/syn.20549.

20.

ITI-007 demonstrates brain occupancy at serotonin 5-HT₂A and dopamine D₂ receptors and serotonin transporters using positron emission tomography in healthy volunteers.

Davis RE, Vanover KE, Zhou Y, Brašić JR, Guevara M, Bisuna B, Ye W, Raymont V, Willis W, Kumar A, Gapasin L, Goldwater DR, Mates S, Wong DF.

Psychopharmacology (Berl). 2015 Aug;232(15):2863-72. doi: 10.1007/s00213-015-3922-1.

PMID:
25843749
Items per page

Supplemental Content

Support Center